The project cost ₹ 7.7 million (INR).
The goal of the proposed project is to develop a tumor necrosis factor alpha (TNF-α) inhibiting first-in-class, orally bioavailable anti-neuroinflammatory small molecule drug treatment for neurocognitive dysfunction. The primary disease indication for our TNF-α inhibiting thionylated thalidomide compounds (thiothalidomides) is Alzheimer's disease (AD).